Acetylcysteine | CAS# 616-91-1 | Anti-bronchitis agent

Acetylcysteine
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 571510

CAS#: 616-91-1

Description: Acetylcysteine has been used to control irritability and aggressive behaviors in patients with autism and other neuropsychiatric disorders. Acetylcysteine has also been used in the treatment of patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD).

Chemical Structure

Acetylcysteine

CAS# 616-91-1

Instruction

Theoretical Analysis

MedKoo Cat#: 571510
Name: Acetylcysteine
CAS#: 616-91-1
Chemical Formula: C5H9NO3S
Exact Mass: 163.03
Molecular Weight: 163.190
Elemental Analysis: C, 36.80; H, 5.56; N, 8.58; O, 29.41; S, 19.65

Price and Availability

Size	Price	Availability
10g	USD 190	2 Weeks
50g	USD 310
100g	USD 500
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: Acetylcysteine; Parvolex; Mucosil

IUPAC/Chemical Name: Cysteine, N-acetyl-, L-

InChi Key: PWKSKIMOESPYIA-BYPYZUCNSA-N

InChi Code: InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1

SMILES Code: SC[C@@H](C(O)=O)NC(C)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Certificate of Analysis:

View CoA: current batch, Lot#C21M01C04

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 163.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Hernandez SH, Howland M, Schiano TD, Hoffman RS. The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. Clin Toxicol (Phila). 2015;53(10):941-9. doi: 10.3109/15563650.2015.1100305. Epub 2015 Oct 20. PubMed PMID: 26484583.

2: Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015 Sep;24(137):451-61. doi: 10.1183/16000617.00002215. Review. PubMed PMID: 26324807.

3: Stutzman D, Dopheide J. Acetylcysteine for treatment of autism spectrum disorder symptoms. Am J Health Syst Pharm. 2015 Nov 15;72(22):1956-9. doi: 10.2146/ajhp150072. PubMed PMID: 26541950.

4: McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs. 2014 Feb;28(2):95-106. doi: 10.1007/s40263-014-0142-x. Review. PubMed PMID: 24442756; PubMed Central PMCID: PMC4009342.

5: Racz R, Sweet BV, Sohoni P. Oral acetylcysteine for neuropsychiatric disorders. Am J Health Syst Pharm. 2015 Jun 1;72(11):923-6, 928-9. doi: 10.2146/ajhp140732. Review. PubMed PMID: 25987686.

6: Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 2013 Mar;34(3):167-77. doi: 10.1016/j.tips.2013.01.001. Epub 2013 Jan 29. Review. PubMed PMID: 23369637.

7: Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013 Aug;1830(8):4117-29. doi: 10.1016/j.bbagen.2013.04.016. Epub 2013 Apr 22. Review. PubMed PMID: 23618697.

8: Heard K, Rumack BH, Green JL, Bucher-Bartelson B, Heard S, Bronstein AC, Dart RC. A single-arm clinical trial of a 48-hour intravenous N-acetylcysteine protocol for treatment of acetaminophen poisoning. Clin Toxicol (Phila). 2014 Jun;52(5):512-8. doi: 10.3109/15563650.2014.902955. Epub 2014 Apr 8. PubMed PMID: 24708414.

9: Fukumoto M. [N-acetylcysteine]. Chudoku Kenkyu. 2013 Jun;26(2):129-33. Review. Japanese. PubMed PMID: 23855246.

10: de Andrade KQ, Moura FA, dos Santos JM, de Araújo OR, de Farias Santos JC, Goulart MO. Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine. Int J Mol Sci. 2015 Dec 18;16(12):30269-308. doi: 10.3390/ijms161226225. Review. PubMed PMID: 26694382; PubMed Central PMCID: PMC4691167.

11: Miller JL, Angulo M. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A. 2014 Feb;164A(2):421-4. doi: 10.1002/ajmg.a.36306. Epub 2013 Dec 5. PubMed PMID: 24311388.

12: McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, Matthews AG, Sharma G, Van Veldhuisen P, Vandrey RG, Levin FR, Weiss RD, Lindblad R, Allen C, Mooney LJ, Haynes L, Brigham GS, Sparenborg S, Hasson AL, Gray KM. Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials. 2014 Nov;39(2):211-23. doi: 10.1016/j.cct.2014.08.011. Epub 2014 Aug 30. PubMed PMID: 25179587; PubMed Central PMCID: PMC4252394.

13: Chiew AL, Isbister GK, Duffull SB, Buckley NA. Evidence for the changing regimens of acetylcysteine. Br J Clin Pharmacol. 2016 Mar;81(3):471-81. doi: 10.1111/bcp.12789. Epub 2015 Nov 23. Review. PubMed PMID: 26387650; PubMed Central PMCID: PMC4767192.

14: Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):231-40. doi: 10.1016/j.jaac.2012.12.020. PubMed PMID: 23452680; PubMed Central PMCID: PMC3745012.

15: Mlejnek P, Dolezel P. N-acetylcysteine prevents the geldanamycin cytotoxicity by forming geldanamycin-N-acetylcysteine adduct. Chem Biol Interact. 2014 Sep 5;220:248-54. doi: 10.1016/j.cbi.2014.06.025. Epub 2014 Jul 3. PubMed PMID: 24998639.

16: Hildebrandt W, Sauer R, Bonaterra G, Dugi KA, Edler L, Kinscherf R. Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status. Am J Clin Nutr. 2015 Nov;102(5):1014-24. doi: 10.3945/ajcn.114.101964. Epub 2015 Oct 7. PubMed PMID: 26447155.

17: Atabek Yigit E, Ercal N. Release of N-acetylcysteine and N-acetylcysteine amide from contact lenses. Eye Contact Lens. 2013 Sep;39(5):335-40. doi: 10.1097/ICL.0b013e3182a2f8bc. PubMed PMID: 23945523.

18: Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One. 2013;8(1):e55124. doi: 10.1371/journal.pone.0055124. Epub 2013 Jan 30. PubMed PMID: 23383076; PubMed Central PMCID: PMC3559541.

19: Zhou J, Coles LD, Kartha RV, Nash N, Mishra U, Lund TC, Cloyd JC. Intravenous Administration of Stable-Labeled N-Acetylcysteine Demonstrates an Indirect Mechanism for Boosting Glutathione and Improving Redox Status. J Pharm Sci. 2015 Aug;104(8):2619-26. doi: 10.1002/jps.24482. Epub 2015 Jun 5. PubMed PMID: 26052837.

20: Savion N, Izigov N, Morein M, Pri-Chen S, Kotev-Emeth S. S-Allylmercapto-N-acetylcysteine (ASSNAC) protects cultured nerve cells from oxidative stress and attenuates experimental autoimmune encephalomyelitis. Neurosci Lett. 2014 Nov 7;583:108-13. doi: 10.1016/j.neulet.2014.09.034. Epub 2014 Sep 26. PubMed PMID: 25263785.

Your view history

Acetylcysteine featured